Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients

†Contributed equally
BMC Cancer201818:590

https://doi.org/10.1186/s12885-018-4497-0

©  The Author(s). 2018

  • Received: 2 March 2017
  • Accepted: 9 May 2018
  • Published:
Open Peer Review reports

Abstract

Background

The expression alterations of B4GALT1 have been noted in some types of cancer and they are related to cancer cell proliferation, invasiveness, metastasis, and drug resistance. We aimed to establish the expression of B4GALT1 in bladder cancer and its connection to patient outcomes, as well as forecasting the advantages of adjuvant chemotherapy (ACT) in patients with muscle-invasive bladder cancer (MIBC).

Methods

There were 142 and 112 MIBC patients who were consecutively recruited and treated via radical cystectomy from 2008 to 2012 in Shanghai Zhongshan Hospital and Fudan University Shanghai Cancer Center (FUSCC), respectively. Tissue microarrays (TMAs) were constructed in triplicate from specimens that had been fixed in formalin and embedded in paraffin samples. Immunohistochemistry was conducted to evaluate B4GALT1 expression in tumor cores, the connection between B4GALT1 expression and patients’ clinical characteristics, and clinical results.

Results

B4GALT1 expression was not connected to clinical prognosis markers, but it was linked to overall survival (OS) (P = 0.013 and P = 0.010, respectively) in the two groups. Moreover, the high levels of B4GALT1 expression were independent indicators of poor OS (P = 0.026 and P = 0.046, respectively). Inclusion of B4GALT1 in the prognostic model revealed a greater predictive accuracy than the primary models. In addition, no differences were observed between B4GALT1 expression (low vs. high) and CD8+ T cell infiltration density (number/cm2) within tumor cores, but there was a positive Pearson correlation between B4GALT1 expression and expression of inhibitory receptor ligands, such as PD-L1 and CTLA4. Most significantly, the advantage of ACT noted in pT3/4 or N+ bladder cancer patients with low B4GALT1 expression was greater than in patients with a high B4GALT1 expression.

Conclusions

Our evaluation indicated that B4GALT1 may be a possible prognosticator of MIBC, and it may be a predictive marker for the choice of ACT in pT3/4 or N+ patients.

Keywords

  • Adjuvant chemotherapy
  • B4GALT1
  • Muscle-invasive bladder cancer
  • Overall survival
  • Prognosis

Background

The fourth most frequently diagnosed cancer, bladder cancer has an occurrence rate of about 7%, and is the eighth most frequent cause of mortality in men (about 4%) [1]. In 2015, it was predicted that there would be 80,500 new bladder cancer cases, with an estimate for deaths of both sexes in China of 32,900 [2]. Even though substantial advancements have been made in bladder cancer treatments, patient prognosis remains poor due to the heterogeneity of the features of this disease [3]. While radical cystectomy is curative in patients with muscle-invasive bladder cancer (MIBC), about 50% of patients experience metastatic recurrence and eventually die from the disease [4]. Each of the urological guidelines suggests neoadjuvant chemotherapy for MIBC patients; however, some evaluations have shown that just 1–15% of MIBC patients are administered neoadjuvant chemotherapy [5]. These same evaluations show that adjuvant chemotherapy (ACT) is given as frequently—or more frequently—than neoadjuvant chemotherapy in daily clinical practice. This outcome has led to the requirement of a precise prognosis evaluation following radical surgery, which is necessary for decision-making about treatment, patient counseling, and assistance in defining ACT indications [6].

Glycans take part in various aspects of the immune response and have been reported to be involved in cancer immune surveillance [7]. Altered cells can be removed by immune effector cells, causing immune selection of tumor cell variants with lowered immunogenicity and resistance to immune effector cells, such as CD8+ T cells and NK cells [8]. Not long ago, an evaluation demonstrated that the ratio of CD8 to Treg tumor-infiltrating lymphocytes is related to the reaction to cisplatin-based neoadjuvant chemotherapy in MIBC patients, which indicates that the immune system has a pivotal part in platinum-based chemotherapy’s effectiveness in treating bladder cancer [9].

The β4-galactosyltransferase (B4GALT) family owns seven members and each of those members possesses distinct biological functions on account of different acceptor specificity, tissue distribution, chronological expression [10]. B4GALT1 conjugates galactose to the outer arm of N-acetylglucosamine in N-linked oligosaccharides of IgG, and B4GALT1 levels are connected to a continuation of the terminal galactose in IgG [11], relating it to the adaptive immune reaction. The significance of glycan β4-galactosylation of the glycans is well known, and this galactosylation could be part of numerous biological activities, such as cancer advancement. The expression alteration of the B4GALTs have been documented in some types of cancer, such as breast cancer [12], colon cancer [11], hepatocellular cancer [13], lung cancer [14], leukemia [15], neuroblastoma [16], and prostate cancer [17] and are connected to cancer cell proliferation, invasiveness, metastasis, and drug resistance.

As our prior evaluations on B4GALT1 in leukemia [15], hepatocellular cancer [13], and renal cancer [18] indicated its pivotal part in cancer biology, we used IHC to analyze B4GALT1 expression in MIBC clinical samples and to determine its connection to clinicopathological features and patients’ overall survival (OS). We further used subgroup analysis, by combining the two cohorts of pT3/4 or N+ patients, to evaluate the association of this biomarker for the benefit from adjuvant chemotherapy.

Methods

Patients and clinical databases

Two consecutive groups of 142 and 112 bladder cancer patients that had been treated via radical cystectomy between March 2008 and December 2012 in Shanghai Zhongshan Hospital and Fudan University Shanghai Cancer Center were chosen retrospectively. The clinical characteristics of patients, their laboratory data, and treatment strategies were acquired from in-patient medical records, and follow-up information was gathered by trained nurses. The evaluation was authorized by the Clinical Research Ethics Committee of Fudan University Shanghai Cancer Center and Zhongshan Hospital, Fudan University. All of the participants in this evaluation were well informed about the details, and informed consent was acquired. Participants were chosen based on the criteria: 1) patients were at least 18 years of age; 2) there was a verified histopathological diagnosis; and 3) TNM classification was re-examined based on the 2010 AJCC. Those patients received neoadjuvant chemotherapy (eight and 11 in the two cohorts, respectively) were excluded from analysis. Additional inclusion criteria were the following: tissue blocks embedded in paraffin could be used for immunohistochemical staining and full results data were accessible. OS was determined from the date of surgery to the date of death or last follow-up visit. An experienced radiologist evaluated responses and advancement, which were established by typical criteria. The course of treatment about ACT and after recurrence was platinum based chemotherapy followed the CUA guideline. Both cohorts last follow up ended on July 2016, and the median follow-up for the two cohorts was 34.0 and 64.5 months, respectively.

TCGA dataset and RNAseq expression data from Bladder Urothelial Carcinoma (BLCA) samples were acquired from the TCGA data portal (https://portal.gdc.cancer.gov/). Tumor transcriptomic profiles of 20,534 genes were measured in 436 primary bladder cancer patients, but only 407 MIBC patients with intact clinical information, especially the follow-up data, were included in this study. The CIBERSORT method was applied to the TCGA database to analyze the difference between B4GALT1 and tumor CD8+ T cell infiltration density, which could infer leukocyte representation in bulk tumor transcriptomes [19].

Immunohistochemistry

The construction of tissue microarrays was carried out as previously detailed [20]. Immunohistochemical staining was carried out with primary anti-B4GALT1 antibody (diluted 1:100; HPA010806; Sigma-Aldrich). Sample staining intensity was assessed by two separate pathologists blinded to patient clinicopathological data and clinical results. A semi-quantitative immunoreactivity scoring (IRS) system was utilized for this examination, as documented elsewhere [21], and it varied from 0 to 300, deriving from the multiplication of intensity of immunohistochemical staining (0, no staining; 1, weak; 2, moderate; and 3, strong) and percentage of positive tumor cells (10 points for each 10% increment; the percentage of positive tumor cells ranged from 0 to 100). X-tile software, version 3.6.1 (Yale University, New Haven, Connecticut) was used to choose the optimum cut-off scores of 120 and 136 for the staining intensities to divide patients into high or low B4GALT1 expression cohorts, respectively.

Statistical analysis

MedCalc 15.8 and Stata 12.0 were utilized for statistical analysis. Categorical data were examined with Fisher exact or chi-square tests. Numerical data were evaluated with the Student’s t test. Subgroup OS curves were determined by the Kaplan-Meier technique and contrasted via log-rank test. We utilized univariate and multivariate Cox proportional hazard models to examine the HR and 95% CI. Prognostic factor accuracy was examined by Harrell’s concordance index (C-index). Moreover, the Akaike information criterion (AIC) value was calculated to assess the prognostic models’ discriminatory capabilities, and decreased AIC values indicated greater predictive ability. Each of the statistical tests was two-sided, and P < 0.05 was established as being statistically significant.

Results

B4GALT1 intensity by IHC and its connection to MIBC pathological characteristics

To evaluate if B4GALT1 expression is connected to MIBC evolution and advancement, we initially examined its expression by IHC in the training and validation groups. As shown in Fig. 1b and e, B4GALT1-positive staining was mainly found in the cytoplasm and shown as a dot-shaped stain. We also presented the negative control in Fig. 1c, and normal urothelium showed a very low even negative expression of B4GALT1 in Fig. 1f. Urothelium tumor grade did not associate with the expression of B4GALT1, as presented in Fig. 1a and b both were low grade tumor with low and high expression respectively, while high grade tumor in Fig. 1d and e as the same. Based on the cut-off value obtained from the IRS score by X-tile discussed in the Methods section, we divided the two groups into low (n = 55 and n = 57) and high (n = 87 and n = 55) B4GALT1 expression cohorts, respectively.
Fig. 1
Fig. 1

B4GALT1 expression in muscle-invasive bladder cancer (MIBC) tissues. Representative B4GALT1 immunohistochemical images of low expression (a) and high expression (b) in low pathological grade MIBC tissues; representative B4GALT1 immunohistochemical images of low expression (d) and high expression (e) in high pathological grade MIBC tissues; negative image by isotype control in bladder tissue (c); representative B4GALT1 immunohistochemical image in normal urothelium (f). Scale bars (black lines) = 100 um. (Magnification 200×)

In-depth patient attributes and the relationship between B4GALT1 expression and patient clinicopathological characteristics are included in Table 1. Seventy-five patients (52.8%) died in the training group due to all causes throughout the follow-up period, while 48 patients (42.9%) in the validation group died. The two groups were largely paired for the primary pathological characteristics as revealed in the Additional file 1: Table S1. B4GALT1 expression was significantly connected to tumor grade in the training group but not in the validation group (P = 0.017 and P = 0.950, respectively; Table 1). This may explain by few patients with low grade tumor in both cohorts (24 and 11 in the two cohorts, respectively), as most patients treated by radical cystectomy were high risk superficial bladder tumor or MIBC. In addition, the expression of B4GALT1 was not associated with patients’ age or gender and not with other confirmed prognosis factors, such as tumor size, pT stage, lymphovascular invasion (LVI) or Charlson Comorbidity Index (CCI) in both the training cohort and validation cohort (all P > 0.05 showed in Table 1).
Table 1

Association between B4GALT1 expression and patient characteristics

Characteristic

Training set (n = 142)

Validation set (n = 112)

Patients

B4GALT1 expression

Patients

B4GALT1 expression

NO.

%

Low

High

P

NO.

%

Low

High

P

Age, years

    

0.614

    

0.763

 Mean ± SD

62.4 ± 10.8

 

61.8 ± 10.9

62.7 ± 10.8

 

61.5 ± 8.7

 

61.8 ± 9.7

61.3 ± 7.6

 

 Range, median

30–82,62

 

34–82,62

30–82,62

 

35–81,62

 

35–81,62

46–75,61

 

Gender

    

0.925

    

0.581

 Male

118

83.1

45

73

 

97

86.6

48

49

 

 Female

24

16.9

10

14

 

15

13.4

9

6

 

Tumor size, cm

    

0.053

    

0.411

 Mean ± SD

3.8 ± 1.9

 

4.2 ± 2.1

3.6 ± 1.7

 

3.8 ± 1.8

 

3.9 ± 2.0

3.7 ± 1.6

 

 Range

0.5–10.0

 

1.0–10.0

0.5–8.0

 

0.8–9.5

 

0.8–9.5

1.3–9.0

 

pT stage

    

0.971

    

0.720

 T2

68

47.9

27

41

 

49

43.8

27

22

 

 T3

48

33.8

18

30

 

49

43.8

23

26

 

 T4

26

18.3

10

16

 

14

12.4

7

7

 

Grade

    

0.017

    

0.950

 low

24

16.9

15

9

 

11

9.8

6

5

 

 high

118

83.1

40

78

 

101

90.2

51

50

 

LVI

    

0.157

    

0.741

 absent

53

37.3

25

28

 

78

69.6

41

37

 

 present

89

62.7

30

59

 

34

30.4

16

18

 

CCI

    

0.116

    

0.263

  ≤ 1

47

33.1

23

24

 

44

39.3

19

25

 

  ≥ 2

95

66.9

32

63

 

68

60.7

38

30

 

High B4GALT1 expression is connected to worse OS in MIBC patients, and B4GALT1 expression is a separate indicator of poor survival

Kaplan–Meier survival analysis was used to contrast OS based on B4GALT1 expression. Patients who exhibited high levels of B4GALT1 expression had a significantly poorer OS in the training and validation groups (log-rank test P = 0.013 and P = 0.010, respectively; Fig. 2a and b). To examine if this discovery was separate from well-established prognostic indicators, such as pathological T stage, tumor grade, LVI, and CCI, we conducted Cox proportional hazard analyses (univariate and multivariate) of each of the clinicopathological variables with B4GALT1 expression.
Fig. 2
Fig. 2

Overall survival (OS) analysis of patients with MIBC based on B4GALT1 expression. Kaplan-Meier analysis of OS in training cohort (n = 142) (left) and in validation cohort (n = 112) (right). P value was calculated by log-rank test

Univariate Cox regression analysis showed that tumor pT stage (pT4 vs. pT2, HR = 1.765, 95%CI: 1.005~ 3.100, P = 0.049) and B4GALT1 expression (HR = 1.849, 95%CI: 1.126~ 3.035, P = 0.016) were associated with OS in the training cohort (Table 2). However, in the validation cohort, patients’ age (HR = 1.062, 95%CI: 1.020~ 1.105, P = 0.004), pT stage (pT3 vs. pT2, HR = 2.708, 95%CI:1.426~ 5.142, P = 0.003); pN stage (HR = 1.626, 95%CI: 1.194~ 2.213, P = 0.002); LVI (HR = 1.926, 95%CI: 1.073~ 3.456, P = 0.029); TNM stage (III vs. II, HR = 3.291, 95%CI: 1.471~ 7.362, P = 0.004; IV vs. II, HR = 6.290, 95%CI: 2.874~ 13.768, P < 0.001), and B4GALT1 (HR = 2.158, 95%CI: 1.187~ 3.923, P = 0.012) were identified as risk factors.
Table 2

Univariate and multivariate Cox regression analysis of overall survival of the two cohorts

 

Univariate

Multivariate

HR

95%CI

P

HR

95%CI

P

Training cohort

 Age(continuous)

1.006

0.986 ~  1.025

0.574

1.004

0.985 ~  1.024

0.661

 Gender(male vs female)

0.697

0.383 ~  1.268

0.240

   

 B4GALT1(high vs low)

1.849

1.126 ~  3.035

0.016

1.773

1.075 ~  2.924

0.026

 CCI(≥2 vs ≤1)

1.154

0.712 ~  1.872

0.563

   

 LVI(present vs absent)

1.449

0.898 ~  2.339

0.131

   

 pN(N+ vs N-)

1.651

0.718 ~  3.795

0.240

   

 pT stage

  pT3 vs pT2

1.063

0.625 ~  1.808

0.824

   

  pT4 vs pT2

1.765

1.005 ~  3.100

0.049

   

 TNM stage

  III vs II

1.278

0.797 ~  2.051

0.312

1.220

0.759 ~  1.961

0.414

  IV vs II

1.877

0.784 ~  4.492

0.159

1.636

0.680 ~  3.938

0.274

Validation cohort

 Age(continuous)

1.062

1.020 ~  1.105

0.004

1.050

1.006 ~  1.095

0.025

 Gender(male vs female)

0.929

0.369 ~  2.337

0.876

   

 B4GALT1(high vs low)

2.158

1.187 ~  3.923

0.012

1.862

1.016 ~  3.413

0.046

 CCI(≥2 vs ≤1)

1.847

0.993 ~  3.438

0.054

   

 LVI(present vs absent)

1.926

1.073 ~  3.456

0.029

1.060

0.458 ~  2.452

0.893

 pN(N+ vs N-)

1.626

1.194 ~  2.213

0.002

   

 pT stage

  pT3 vs pT2

2.708

1.426 ~  5.142

0.003

   

  pT4 vs pT2

2.517

0.967 ~  6.550

0.060

   

 TNM stage

  III vs II

3.291

1.471 ~  7.362

0.004

2.555

1.126 ~  5.796

0.026

  IV vs II

6.290

2.874 ~  13.768

< 0.001

5.230

1.962 ~  13.943

0.001

After that, multivariate Cox regression analysis, including potential risk factors determined by univariate Cox analysis, was conducted. In addition to TNM stage, age, and LVI, B4GALT1 was shown to be an independent prognostic factor for OS (shown in Table 2, dichotomous B4GALT1: HR = 1.773, 95%CI: 1.075~ 2.924, P = 0.026 in training cohort; HR = 1.862, 95%CI: 1.016 ~ 3.413, P = 0.046 in validation cohort).

Prognostic models with B4GALT1 expression: Extension for MIBC patients

To additionally evaluate the prognostic ability of B4GALT1 expression as a prognosticator, we created prognostic models that combine B4GALT1 expression with TNM stage and tumor grade by C-index for comparison of their prognostic reliability. As shown in Table 3, in the training group, the C-indices were 0.644 and 0.700 when evaluated with B4GALT1 alone and TNM + Grade, respectively, and they were enhanced to 0.744 when the dichotomous B4GALT1 expression signature was placed in the combination model. Similarly, in the validation group, the C-index was enhanced from 0.637 and 0.679 to 0.746 when dichotomous B4GALT1 signature was placed into the model. Moreover, P values suggesting the statistical significance of C-indices of the amalgamated TNM + Grade + B4GALT1 model vs. only B4GALT1 or TNM + Grade were all < 0.05 in the two cohorts.
Table 3

Comparison of the accuracy of the prognostic models and B4GALT1 expression for overall survival

Model

 

Training cohort

 

Validation cohort

C-index

95% CI

P value

C-index

95% CI

P value

B4GALT1 (high vs. low)

0.644

0.558 ~  0.741

0.016

0.637

0.548 ~  0.726

0.028

TNM + Grade

0.700

0.606 ~  0.783

0.031

0.679

0.591 ~  0.766

0.039

TNM + Grade + B4GALT1

0.744

0.653 ~  0.822

 

0.746

0.648 ~  0.835

 

Note: P values indicating statistical significance of C-indices of combined TNM + Grade + B4GALT1 vs only B4GALT1 or TNM + Grade

B4GALT1 expression and the benefit from ACT in pT3/4 or N+ patients

For patients of pT3/4 or N+ bladder cancer, ACT has improved survival rate and has become more often used in clinical practice than neoadjuvant chemotherapy. In our datasets, few patients used neoadjuvant chemotherapy but 41% patients received ACT. To explore the association of the B4GALT1 expression signature with response to platinum-based ACT, subgroup analysis was performed in these patients. As presented in Fig. 3, the combined patients with pT3/4 or N+ diseases showed better survival with ACT compared to without ACT (log-rank test P = 0.025). By incorporating B4GALT1 signature into ACT information, the low B4GALT1 expression subgroup, patients with ACT had more survival benefit than patients without ACT (log-rank test P = 0.017). On the contrary, high B4GALT1 group patients did not have benefit from ACT (log-rank test P = 0.423).
Fig. 3
Fig. 3

Relationship between B4GALT1 expression and benefit from adjuvant chemotherapy (ACT). Survival curves for pT3/4 or N+ patients with ACT and without ACT in combined cohorts (left) and in low B4GALT1 expression subgroup (middle) and in high B4GALT1 expression subgroup (right). P value was calculated by log-rank test

B4GALT1 expression in MIBC was associated with tumor immunosuppressive status

To examine the mechanism of low B4GALT1 expression that provides patients with advantages from ACT, we considered that the immune system, in particular the efficient immune cells, has a crucial part in the reaction of bladder cancer to chemotherapy. Unfortunately, no differences between B4GALT1 expression (low vs. high) and CD8+ T cell infiltration density (number/cm2) within tumor cores in the Zhongshan cohort (Fig. 4a), FUSCC cohort (Fig. 4b) and TCGA_BLCA cohort calculated by CYBERSORT method (Fig. 4c). Since glycans control different features of the immune reaction hindering tumor surveillance, we determined if the B4GALT1 expression was linked to inhibitory receptor ligands in tumors, such as PD-L1 and CTLA4, whose humanized antibodies have demonstrated groundbreaking clinical outcomes in patients with bladder cancer. And positive Pearson correlation between B4GALT1 and PD-L1 expression in Fig. 4d (r = 0.24, P < 0.001) and CTLA4 expression in Fig. 4e (r = 0.18, P < 0.001) were found in the TCGA dataset.
Fig. 4
Fig. 4

B4GALT1 expression in MIBC was associated with tumor immunosuppressive status. No differences between B4GALT1 expression (low vs. high) and CD8+ T cell infiltration density (number/cm2) within tumor cores in Zhongshan cohort (a), FUSCC cohort (b) and TCGA_BLCA cohort calculated by CYBERSORT method (c); the positive Pearson correlation between B4GALT1 and PD-L1 expression (d) and CTLA4 expression (e) in TCGA dataset

Discussion

Of the constructed bladder cancer prognostic models, the American Joint Committee on Cancer (AJCC) TNM staging system, which has been properly confirmed, is the most broadly utilized prognostic model to forecast results in patients treated with radical cystectomy. Nevertheless, a large weakness of this system is the difficulty in integrating new clinical information, including molecular markers or more elaborate bioinformatics. Moreover, the established staging systems are less reliable than several of the prediction models integrating clinical data in the time of personalized medicine [22]. In our evaluation, the integration of B4GALT1 into TNM staging might elevate the risk stratification of MIBC patients. We found a negative correlation between B4GALT1 and MIBC outcome and validated B4GALT1 as an independent prognosis marker in two independent cohorts for OS in MIBC patients.

Clinical practice guidelines provide diverse guidance to ACT in MIBC, with the National Comprehensive Cancer Network guidelines encouraging ACT as a low (2B) suggestion [23], but the European Association of Urology guidelines indicate that there is not adequate data to encourage the typical administration of chemotherapy [24]. In a big observational evaluation, ACT was connected to increased survival in patients with locally progressed bladder cancer postcystectomy [25]. Some studies reveal that ACT is administered more often than neoadjuvant chemotherapy in real clinical practice [5]. This situation is consistent with our study that 41% locally advanced patients received ACT but few patients to neoadjuvant chemotherapy. So the selection of proper patients for ACT has its practical significance. We found that among locally advanced patients with ACT or without ACT, the former group had survival benefit. When incorporating B4GALT1 signature, low B4GALT1 expression subgroup patients with ACT had more survival benefit than patients without ACT, but high B4GALT1 expression subgroup patients had no benefit from ACT, indicating that B4GALT1 expression could be an important factor for the efficiency of chemotherapy. This will assist in choosing and handling patients who will be administered ACT.

To explore the underlying mechanisms of low B4GALT1 expression patients benefit from ACT, we figured that the efficient immune cells have a pivotal part in the reaction of bladder cancer to chemotherapy, which is supported by a recent study [9]. But we found no difference of CD8+ T cell infiltration density in two B4GALT1 patients group in our cohorts and neither in TCGA dataset. As glycans regulate immune response interfering with tumor surveillance [26], we explored whether the B4GALT1 expression was associated with PD-L1 and CTLA4, whose humanized antibodies have shown unprecedented clinical results in patients with MIBC, and both had positive spearman correlation, indicating that tumor cell of high expression B4GALT1 could form more potent immunosuppressive microenvironment. Engagement of inhibitory receptors (IRs) on interaction with their cognate ligands leads to dimming of T-cell receptor signaling, resulting in a reduction in immune responses to antigens [27]. IRs expression has been associated with T-cell exhaustion in cancers, leading to T-cell impotence in tumor eradication [28]. Low doses chemotherapy agents, including cisplatin, selectively inhibit regulatory and suppressor cells [29]. To sum up, these results have given us the rationale for combining checkpoint receptor inhibition with chemotherapy in the future.

The biggest limitations of this evaluation are its retrospective design and relatively minute sample size. In addition, each of the specimens was gathered from two tertiary referral hospitals, so the outcomes should be further confirmed or reassessed in bigger datasets and external heterogeneous groups. Additional expanded population evaluation on this and prospective external validation are needed.

Conclusions

Our evaluation indicated that B4GALT1 may be a possible prognosticator of MIBC, and it may be a marker for predicting choice of adjuvant chemotherapy in locally progressed patients. High expression of B4GALT1 could bring about more potent immunosuppressive microenvironment, and could help make better selection of MIBC patients for combined therapy with chemotherapy and immunotherapy.

Notes

Abbreviations

ACT: 

Adjuvant chemotherapy

B4GALT1: 

Beta-1,4-galactosyltransferase

CCI: 

Charlson Comorbidity Index

FUSCC: 

Fudan University Shanghai Cancer Center

IRs: 

Inhibitory receptors

LVI: 

Lymphovascular invasion

MIBC: 

Muscle-invasive bladder cancer

OS: 

Overall survival

TMAs: 

Tissue microarrays

Declarations

Acknowledgments

The authors would like to thank Dr. Qifeng Wang (Department of Pathology, Fudan University Shanghai Cancer Center) and Ms. Haiying Zeng (Department of Pathology, Zhongshan Hospital of Fudan University) for diagnosis confirmation and technical assistance, respectively. We thank LetPub for its linguistic assistance during the preparation of this manuscript.

Funding

This study was funded by grants from National Key Projects for Infectious Diseases of China (2012ZX10002012–007, 2016ZX10002018–008), the National Natural Science Foundation of China (31270863, 81402082, 81472227, 81472377 and 81672544), the Program for New Century Excellent Talents in University (NCET-13-0146), the Shanghai Municipal Natural Science Foundation (16ZR1406500) and the Shanghai Municipal Commission of Health and Family Planning Program (20144Y0223). None of the study sponsors had a role in study design or the collection, analysis, and interpretation of data.

Availability of data and materials

The datasets used and/or analyzed in this study are available on request from the corresponding author.

The TCGA dataset is publicly available from the TCGA data portal (https://portal.gdc.cancer.gov/).

Authors’ contributions

HX and YZ were involved in the acquisition, analysis and interpretation of data, statistical analysis and manuscript writing; JZ, ZL and HF acquired the tumor blocks and constructed the TMAs; YC, GL and BD stained the tumor tissue and scored the IHC staining; JX and DY developed the study concept and design, reviewed and edited the manuscript, obtained funding and provided supervision for the study. All authors have read and approved the final version of the manuscript.

Ethics approval and consent to participate

The study was approved both by the Clinical Research Ethics Committee of Fudan University Shanghai Cancer Center and Zhongshan Hospital, Fudan University. Patients gave written informed consent prior to collection of any specimens.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Urology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, 270 Dong’an Road, Shanghai, 200032, China
(2)
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
(3)
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 138 Yixuyuan Road, Shanghai, 200032, China

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.View ArticlePubMedGoogle Scholar
  2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.View ArticlePubMedGoogle Scholar
  3. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374(9685):239–49.View ArticlePubMedGoogle Scholar
  4. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66.View ArticlePubMedGoogle Scholar
  5. Reardon ZD, Patel SG, Zaid HB, Stimson CJ, Resnick MJ, Keegan KA, Barocas DA, Chang SS, Cookson MS. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur Urol. 2015;67(1):165–70.View ArticlePubMedGoogle Scholar
  6. Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, Cote RJ, Urun Y, Chang SL, Choueiri TK, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014;66(1):42–54.View ArticlePubMedGoogle Scholar
  7. Macauley MS, Crocker PR, Paulson JC. Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol. 2014;14(10):653–66.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15(9):540–55.View ArticlePubMedGoogle Scholar
  9. Baras AS, Drake C, Liu JJ, Gandhi N, Kates M, Hoque MO, Meeker A, Hahn N, Taube JM, Schoenberg MP, et al. The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. Oncoimmunology. 2016;5(5):e1134412.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Zhou H, Ma H, Wei W, Ji D, Song X, Sun J, Zhang J, Jia L. B4GALT family mediates the multidrug resistance of human leukemia cells by regulating the hedgehog pathway and the expression of p-glycoprotein and multidrug resistance-associated protein 1. Cell Death Dis. 2013;4:e654.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Shinzaki S, Iijima H, Fujii H, Kuroki E, Tatsunaka N, Inoue T, Nakajima S, Egawa S, Kanto T, Tsujii M, et al. Altered oligosaccharide structures reduce colitis induction in mice defective in beta-1,4-galactosyltransferase. Gastroenterology. 2012;142(5):1172–82.View ArticlePubMedGoogle Scholar
  12. Choi HJ, Chung TW, Kim CH, Jeong HS, Joo M, Youn B, Ha KT. Estrogen induced beta-1,4-galactosyltransferase 1 expression regulates proliferation of human breast cancer MCF-7 cells. Biochem Biophys Res Commun. 2012;426(4):620–5.View ArticlePubMedGoogle Scholar
  13. Wei Y, Liu D, Zhou F, Ge Y, Xu J, Yun X, Gu J, Jiang J. Identification of beta-1,4-galactosyltransferase I as a target gene of HBx-induced cell cycle progression of hepatoma cell. J Hepatol. 2008;49(6):1029–37.View ArticlePubMedGoogle Scholar
  14. Zhu X, Jiang J, Shen H, Wang H, Zong H, Li Z, Yang Y, Niu Z, Liu W, Chen X, et al. Elevated beta1,4-galactosyltransferase I in highly metastatic human lung cancer cells. Identification of E1AF as important transcription activator. J Biol Chem. 2005;280(13):12503–16.View ArticlePubMedGoogle Scholar
  15. Zhou H, Zhang Z, Liu C, Jin C, Zhang J, Miao X, Jia L. B4GALT1 gene knockdown inhibits the hedgehog pathway and reverses multidrug resistance in the human leukemia K562/adriamycin-resistant cell line. IUBMB Life. 2012;64(11):889–900.View ArticlePubMedGoogle Scholar
  16. Chang HH, Chen CH, Chou CH, Liao YF, Huang MJ, Chen YH, Wang WJ, Huang J, Hung JS, Ho WL, et al. beta-1,4-galactosyltransferase III enhances invasive phenotypes via beta1-integrin and predicts poor prognosis in neuroblastoma. Clin Cancer Res. 2013;19(7):1705–16.View ArticlePubMedGoogle Scholar
  17. Radhakrishnan P, Chachadi V, Lin MF, Singh R, Kannagi R, Cheng PW. TNFalpha enhances the motility and invasiveness of prostatic cancer cells by stimulating the expression of selective glycosyl- and sulfotransferase genes involved in the synthesis of selectin ligands. Biochem Biophys Res Commun. 2011;409(3):436–41.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Xie H, Zhu Y, An H, Wang H, Zhu Y, Fu H, Wang Z, Fu Q, Xu J, Ye D. Increased B4GALT1 expression associates with adverse outcome in patients with non-metastatic clear cell renal cell carcinoma. Oncotarget. 2016;7(22):32723–30.PubMedPubMed CentralGoogle Scholar
  19. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–7.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Xu L, Zhu Y, Chen L, An H, Zhang W, Wang G, Lin Z, Xu J. Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma. Ann Surg Oncol. 2014;21(9):3142–50.View ArticlePubMedGoogle Scholar
  21. Detre S, Saclani Jotti G, Dowsett M. A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995;48(9):876–8.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Kluth LA, Black PC, Bochner BH, Catto J, Lerner SP, Stenzl A, Sylvester R, Vickers AJ, Xylinas E, Shariat SF. Prognostic and prediction tools in bladder Cancer: a comprehensive review of the literature. Eur Urol. 2015;68(2):238–53.View ArticlePubMedGoogle Scholar
  23. Power NE, Izawa J. Comparison of guidelines on non-muscle invasive bladder Cancer (EAU, CUA, AUA, NCCN, NICE). Bladder cancer. 2016;2(1):27–36.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG, Sherif A, European Association of U. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65(4):778–92.View ArticlePubMedGoogle Scholar
  25. Galsky MD, Stensland KD, Moshier E, Sfakianos JP, McBride RB, Tsao CK, Casey M, Boffetta P, Oh WK, Mazumdar M, et al. Effectiveness of adjuvant chemotherapy for locally advanced bladder Cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(8):825–32.View ArticleGoogle Scholar
  26. Rabinovich GA, Toscano MA. Turning ‘sweet’ on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol. 2009;9(5):338–52.View ArticlePubMedGoogle Scholar
  27. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61.View ArticlePubMedGoogle Scholar
  28. Fuertes Marraco SA, Neubert NJ, Verdeil G, Speiser DE. Inhibitory receptors beyond T cell exhaustion. Front Immunol. 2015;6:310.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Dalgleish AG. Rationale for combining immunotherapy with chemotherapy. Immunotherapy. 2015;7(3):309–16.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement

BMC Cancer

ISSN: 1471-2407

Contact us